ClinicalTrials.gg
CompletedNCT03073057Updated Mar 8, 2017

Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

A Phase 1 interventional study of Budesonide/formoterol and Charcoal in Asthma, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
92nd of 108
20 · median 124
Started
2016
with 5 others
Phase 1
10 of 110
none open now
Registered
85th of 110
by date

Among the 110 studies testing budesonide in Asthma, this one is the 92nd largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2016, is one of 10 in phase 1, and was the 85th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to compare Budesonide/formoterol Easyhaler test products with the marketed product Symbicort Turbuhaler in terms of the drug absorbed into the bloodstream.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained
  • > 19 and \< 30kg/m2, weight at least 50 kg
  • Good general health ascertained by detailed medical history, and laboratory and physical examinations

Exclusion criteria

Exclusion Criteria:

  • Evidence of a cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease
  • Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during a study.
  • Known to the active substance(s) or the of the drug
  • Pregnant and lactating females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Charcoal and Budesonide/formoterol Easyhaler A

    160/4.5microg/inhalation Charcoal

    Drug: Budesonide/formoterol · Other: Charcoal

  • Experimental
    Charcoal and Budesonide/formoterol Easyhaler B

    160/4.5microg/inhalation Charcoal

    Drug: Budesonide/formoterol · Other: Charcoal

  • Experimental
    Charcoal and Budesonide/formoterol Easyhaler C

    160/4.5microg/inhalation Charcoal

    Drug: Budesonide/formoterol · Other: Charcoal

  • Active comparator
    Charcoal and Symbicort Turbuhaler

    160/4.5microg/inhalation Charcoal

    Other: Charcoal · Drug: Symbicort Turbuhaler

Interventions

  • DrugBudesonide/formoterol

    Drug pages: Budesonide · Formoterol

    2 inhalations as a single dose

    Also known as: Budesonide/formoterol 160/4.5microg

  • OtherCharcoal
  • 2 inhalations as a single dose

    Also known as: Symbicort Turbuhaler 160/4.5 microg

06

What researchers measure

Primary outcomes

  1. Cmax of plasma budesonide and formoterol

    Time frame: within 24 hours

  2. AUCt of plasma budesonide and formoterol

    Time frame: within 24 hours

07

Study locations

1 site
  • Orion Pharma, Clinical Pharmacology Unit
    Espoo, 02100, Finland
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Mar 2016, 2 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2016
First posted
Mar 8, 2017
StartActual
Jan 2016
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Last update
Mar 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03073057
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Jan 2016
Primary completion
Mar 2016
Completion
Mar 2016
Last update
Mar 8, 2017

Study contacts

Iissa Kivisto
study director · Orion Corporation, Orion Pharma
Leena Mattila, MD
principal investigator · Orion Pharma, Clinical Pharmacology Unit, Espoo, Finland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Formoterol

Start the discussion